



SHUKRA

PHARMACEUTICALS LTD.

Ref No: - SHUKRAPHAR/SEC/STOCK/2024-25

Date: 14/02/2025

To,
Department of Corporate Services,
BSE Limited,
Phiroze Jeejeebhoy Towers
Dalal Street, Fort,
Mumbai - 400 001.

SECURITY CODE: 524632 || SECURITY ID: SHUKRAPHAR || ISIN: INE551C01028 || SERIES: EQ

Dear Sir/Madam,

Sub.- Integrated Filing (Financial) for the quarter and nine-months ended 31st December 2024.

Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-21C\NP120241185 dated 31st December 2024, read with BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025102 dated 2nd January 2025, we are submitting herewith the Integrated Filing (Financial) for the quarter and nine months ended 31st December 2024.

This information is also being hosted on the Company's website at www.shukrapharmaceuticals.com


You are therefore requested to take note of the same.

Thanking you,

Yours faithfully,

For, Shukra Pharmaceuticals Limited


Bhoomiben Patel
Director
DIN: 083167893



CIN : L24231GJ1993PLC019079



SHUKRA

PHARMACEUTICALS LTD.

SHUKRA PHARMACEUTICALS LIMITED

CIN: L24231GJ1993PLC019079

3rd Floor, Dev House, Opposite WIAA Institute, Judges Bungalow Road, Bodakdev, Ahmedabad - 380054

Email : info@shukrapharmaceuticals.com

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED 31st DECEMBER, 2024

(All amounts in ₹ Lakhs, Unless Otherwise Stated)

Sr. No.	Particulars	QUARTER ENDED			NINE MONTH ENDED		Year Ended
		31.12.2024 (Unaudited)	30.09.2024 (Unaudited)	31.12.2023 (Unaudited)	31.12.2024 (Unaudited)	31.12.2023 (Unaudited)	31.03.2024 (Audited)
1	Income from Operations						
I	Revenue from Operations	1,058.43	555.52	1,889.06	1,931.75	6,368.90	7,457.29
	(a) Net Sales/ Income from Operations	1,058.43	555.52	1,889.06	1,931.75	6,368.90	7,457.29
II	Other Income	100.64	101.74	56.23	274.14	143.84	281.52
	Total Income from Operations (I+II)	1,159.07	657.27	1,945.29	2,205.90	6,512.74	7,738.81
2	Expenses						
(a)	Cost of materials consumed	377.92	145.19	384.85	615.26	1,067.11	1,337.97
(b)	Purchase of Stock-in Trade	0.00	86.28	342.61	86.28	3,040.52	3,040.52
(c)	Changes in inventories of finished goods, and work-in-progress and stock in trade	17.50	6.35	(0.00)	(66.63)	178.62	70.15
(d)	Employee Benefit Expenses	154.82	142.90	135.15	435.99	406.71	564.72
(e)	Finance Cost	15.13	11.11	6.57	32.41	21.52	28.50
(f)	Depreciation & Amortisation Expenses	69.78	69.82	51.17	206.10	153.28	205.02
(g)	Other Expenses	114.44	108.12	72.00	319.83	179.01	503.60
	Total Expenses	749.58	569.78	992.35	1,629.25	5,046.77	5,750.47
3	Profit / (Loss) before Exceptional and Extra ordinary items and Tax (1-2)	409.48	87.49	952.94	576.65	1,465.97	1,988.34
4	Exceptional Items	-	-	-	-	-	-
	Profit / (Loss) before Extra ordinary items and Tax (3-4)	409.48	87.49	952.94	576.65	1,465.97	1,988.34
6	Extra ordinary items	-	-	-	-	-	-
7	Net Profit / (Loss) from Ordinary Activities before Tax(5-6)	409.48	87.49	952.94	576.65	1,465.97	1,988.34
8	Tax Expenses						
I.	Current Tax	88.88	28.80	10.38	144.27	10.38	136.16
II.	Deferred Tax	4.17	4.80	0.38	13.51	0.24	(1.55)
III.	Tax of Earlier Year	-	-	0.00	-	0.23	-
IV.	MAT Credit Entitlement	-	-	-	-	-	-
9	Net Profit / (Loss) for the Period (7-8)	316.44	53.89	942.18	418.87	1,455.12	1,853.73
10	Other Comprehensive Income (net off Tax)	-	-	-	-	-	-
	Remeasurement of defined benefit plans	-	-	-	-	-	-
	Prior Period Adjustments & Expenses	-	-	-	-	-	-
11	Total Comprehensive Income for the period (9+10)	316.44	53.89	942.18	418.87	1,455.12	1,853.73
12	Paid up Equity Share Capital	4,378.79	4,378.79	1,094.70	4,378.79	1,094.70	1,094.70
13	Face Value of Equity Shares	10.00	10.00	10.00	10.00	10.00	10.00
14	Earnings per Share (of Re. 10/- each) :						
(a)	Basic-Rs	0.72	0.12	8.61	0.96	13.29	16.93
(b)	Diluted-Rs	0.72	0.12	8.61	0.96	13.29	16.93

NOTES:

- The above Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its Meeting held on 14th February, 2025. The statutory auditors have carried out review of the results for the quarter ended on 31st December, 2024 and have expressed an unqualified audit opinion.
- The Unaudited Financial Statements are prepared in accordance with the Accounting Standards specified under Section 133 of the Companies Act, 2013 ("Act") read with Companies (Indian Accounting Standards) Rules, 2015 as amended and in the format as prescribed under Regulation 33 of the SEBI (LODR) Regulations, 2015.
- The Financial Results of the Company are available on Company's website and also on the website of BSE Limited, i.e. www.bseindia.com, where the Shares of the Company are listed.
- During the quarter ended 31st December, 2024, 2 complaints were received out of that 2 complaints were disposed off at the end of the quarter.
- The figures for the previous period/year have been regrouped /reclassified, wherever necessary.
- The Company is operating in single segment, so above results are for single segment only.

Place: Ahmedabad
Date: 14-02-2025



For and on behalf of Board of Directors of
SHUKRA PHARMACEUTICALS LIMITED

Dakshesh
Rameshchandra
Shah

Dakshesh Shah
Managing Director
(DIN : 00561666)

Digitally signed by Dakshesh Rameshchandra Shah
DN: cn=Dakshesh Rameshchandra Shah, o=SHUKRA PHARMACEUTICALS LIMITED, email=Dakshesh.Rameshchandra.Shah@shukrapharmaceuticals.com, c=IN
Date: 2025.02.14 16:26:17 +05'30'

CIN : L24231GJ1993PLC019079

Regd. Office : 3rd Floor, "VEER HOUSE" Opp. WIAA Office, Judges Bungalow Road, Bodakdev, Ahmedabad-380 054.
Factory Add. : 795, Rakanpur, Sola-Santej Road, Ta. Kalol, Dist. Gandhinagar-382721, Gujarat, India, Ph. : 02764-286317

Chartered Accountants

INDEPENDENT AUDITOR'S REVIEW REPORT on Standalone Unaudited Quarterly and Year to Date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors,
SHUKRA PHARMACEUTICALS LIMITED
Ahmedabad

1. We have reviewed the accompanying statement of unaudited standalone financial results of **SHUKRA PHARMACEUTICALS LIMITED** (the "Company"), for the quarter ended December 31, 2024 and year to date from April 01, 2024 to December 31, 2024 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (Ind AS) 34 on 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For MAAK and Associates

[Firm Registration No.135024W]

Chartered Accountants



Marmik Shah
Partner
Mem. No. 133926



Place: Ahmedabad
Date: 14th February, 2025
UDIN: 25133926BMJGPP1429

B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC. – Not Applicable

C. FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES – Not Applicable, No default

D. FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS (applicable only for half-yearly filings i.e., 2nd and 4th quarter) – Not Applicable

E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG-WITH ANNUAL AUDITED FINANCIAL RESULTS (Standalone) (applicable only for Annual Filing i.e., 4th quarter) – Not Applicable